首頁 > 市場調查報告書 > 通訊

市場調查報告書

商品編碼

1809466

RET融合遺傳基因的全球市場:市場規模，目標人群，競爭情形，市場預測-2034年

RET Fusion Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

出版日期: 2025年09月01日 | 出版商:

DelveInsight | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

美國研究公司DelveInsight發布的 "全球RET融合基因市場－市場規模、目標族群、競爭格局及2034年預測" 報告，詳細介紹了美國、四個歐盟國家（德國、法國、義大利和西班牙）、英國和日本的RET融合基因、潛在患者群體、競爭格局和未來市場趨勢。

"RET融合基因市場報告" 深入分析了針對RET融合基因患者的現有治療方法、已獲批和新興的RET融合基因、個體療法的市場份額、RET融合基因治療的目標患者群體，以及2020年至2034年七個主要國家按療法和適應症劃分的當前和預測RET融合基因市場規模。本報告還涵蓋了目前未滿足的需求以及將新類別納入治療模式的挑戰、新RET融合基因可用性和接受度的地區差異，以及對RET融合基因報銷的洞察，從而識別最佳機會並評估市場潛力。

目標地區

美國
歐盟四國（德國、法國、義大利、西班牙）、英國
日本

研究期間：2020-2034

RET融合基因概述

本部分提供詳細信息，涵蓋抑制劑的研發歷程，涵蓋從突變和蛋白表達發現到進入臨床開發階段以及未來商業潛力的各個方面。本部分深入探討了抑制劑正在開發的各種適應症，並深入了解了這些抑制劑可能針對的潛在患者群體。此外，本部分也簡要概述了針對每個目標適應症的現有治療方案。

RET 融合基因在臨床上的應用

本節詳細介紹了目前治療模式中針對所有潛在適應症的現有局部和全身治療方案，大多數製藥公司正在積極評估抑制劑。分析新型 RET 融合基因的潛力至關重要，因為這些基因可能會改變目前的臨床實踐指南，尤其是在實際應用中。

本節也涵蓋了生物標記檢測在不同疾病階段的相關性和重要性。此外，還需要了解的是，由於成本、可近性、報銷以及指南不推薦等問題，此類檢測在常規臨床實踐中的實施在不同國家/地區存在差異。

RET 融合基因藥物章節

RET 融合基因報告的藥物章節對市售和後期（III 期和 II 期）療法進行了深入分析。它還可以幫助您了解RET融合基因臨床試驗的詳細資訊、藥理作用、RET融合基因相關協議與合作、審批時間表、專利詳情、優缺點以及最新的新聞和新聞稿。

已上市RET融合基因療法

"RET融合基因療法" 部分提供了已核准療法的詳細藥物概況。這包括臨床開發活動、上市日期、監管里程碑以及安全性和有效性數據的資訊。

新興RET融合基因療法

除了以表格形式呈現的全面的RET融合基因競爭格局外， "新興KRAS抑制劑" 章節還提供了針對各種適應症的中後期臨床開發的新興RET融合基因的產品詳情和其他開發活動。

藥物類別洞察

"藥物類別洞察" 部分提供了關於RET融合基因這一類別的全面資訊。這包括對該類別及其在特定疾病治療中的作用的廣泛概述。洞察涵蓋了RET融合基因的既往臨床開發、其作用機制、亞型以及未來的商業前景。此外，我們還詳細介紹了此類藥物的當前趨勢、挑戰和未來前景。

RET融合基因市場展望

本節詳細介紹了抑制劑臨床開發活動啟動後RET融合基因市場的變化動態。它還對該領域主要公司正在開發的所有療法進行了詳細的總結和比較。本節重點介紹了一種療法相對於另一種療法的優勢，並根據安全性和有效性數據的可用性、每次試驗的患者人數以及試驗納入標準等參數進行了評估。它強調了開發這些標靶療法的重要性，以及這些療法取得商業成功以實現醫生和患者期望的治療目標的必要性。它還總結了活躍於該領域的早期進入者。

RET 融合基因療法的滲透率

本節重點介紹已上市並預計將於 2020 年至 2034 年期間上市的潛在 RET 融合基因藥物的吸收率，具體取決於競爭格局、安全性和有效性數據以及進入順序。重要的是，在關鍵試驗和驗證性試驗中評估新型療法的大型公司必須謹慎選擇合適的對照藥物，以最大限度地提高獲得積極監管反饋的機會，從而獲得批准、順利上市并快速推廣。

RET 融合基因管線開發活動

本報告深入分析了處於 III 期和 II 期的各種候選療法。本報告也分析了參與標靶藥物開發的關鍵參與者。

RET 融合基因管線開發活動

本報告提供了與 RET 融合基因相關的合作、收購、授權和專利細節的全面資訊。

關鍵意見領袖 (KOL) 觀點

為了了解當前和未來的市場趨勢，我們透過一手資料和二手資料研究，諮詢了領先的醫生、治療領域研究人員和其他行業專家，以填補數據空白並驗證我們的二手資料研究。我們聯繫了超過 25 位關鍵意見領袖，以深入了解 RET 融合基因融入不斷發展的治療方法、患者對傳統療法的依賴性、患者對治療轉換的接受度、藥物吸收以及藥物可及性挑戰。

定性分析

我們使用各種方法進行定性和市場情報分析，包括 SWOT 分析和分析師洞察。 SWOT 分析提供了疾病診斷、患者認知度、競爭格局、成本效益和區域治療可及性方面的優勢、劣勢、機會和威脅。這些發現是基於我們分析師的判斷以及對成本分析和現有及不斷發展的治療模式的評估。

市場准入與報銷

本節深入分析了標準醫療費用評估 (HTA) 定價、2024 年的最新改革以及七個主要國家報銷流程的變化。例如，美國採用多付款人模式定價藥品，但近期的聯邦立法，例如 "降低通膨法案" 中關於處方藥價格改革的條款，已顯著改變了某些聯邦體系中的藥品定價體系，目前該體係正在經歷重大變革。同時，德國的市場准入系統與許多其他國家採用的體係不同，因為新藥上市時無需獲得定價和報銷批准。

本節也提供了已獲批准療法的報銷（如有）的詳細資訊。

範圍：

本報告涵蓋關鍵事件、摘要整理、目標族群、流行病學、市場預測、患者人口統計資訊以及各種生物標記檢測率。
此外，本報告全面描述了當前和新興療法，並深入了解了RET融合基因的潛在患者群體。
本報告詳細回顧了RET融合基因市場，包括歷史和預測市場規模、按療法劃分的市場份額、詳細的預測假設以及我們方法的原理。
透過SWOT分析、專家見解/KOL觀點和治療偏好，幫助您在製定業務策略方面佔優勢，從而塑造和推動7個主要國家/地區的RET融合基因市場。
依療法和適應症提供抑制劑的市場規模。

DelveInsight's "RET Fusion Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of RET Fusion, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The RET Fusion market report provides insights around existing treatment practices in patients with RET Fusion, approved (if any) and emerging RET Fusion, market share of individual therapies, patient pool eligible for treatment with RET Fusion, along with current and forecasted 7MM RET Fusion market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new RET Fusion in different geographies, along with insights on RET Fusion pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

The United States
EU4 (Germany, France, Italy, and Spain), and the UK
Japan

Study Period: 2020-2034

RET Fusion Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

RET Fusion in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging RET Fusion in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

RET Fusion Drug Chapters

The drug chapter segment of the RET Fusion report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the RET Fusion clinical trial details, pharmacological action, agreements and collaborations related to RET Fusion, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

RET Fusion Marketed Drugs

The RET Fusion marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

RET Fusion Emerging Drugs

Apart from a comprehensive RET Fusion competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging RET Fusion under the late and mid-stage of clinical development for various indications.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on RET Fusion as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of RET Fusion, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

RET Fusion Market Outlook

This section will include details on changing RET Fusion market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

RET Fusion Drugs Uptake

This section focuses on the uptake rate of potential RET Fusion already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

RET Fusion Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

RET Fusion Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for RET Fusion.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on RET Fusion' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on RET Fusion addressable patient pool
A detailed review of the RET Fusion market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM RET Fusion market.
Market Size of Inhibitors by therapies and indication will be provided

RET Fusion Report Key Strengths

11 Years RET Fusion Market Forecast
The 7MM Coverage
RET Fusion Competitive Landscape of current and emerging therapies
RET Fusion Total Addressable patient population
Drugs Uptake and Key Market Forecast Assumptions
Approved and Emerging therapy Profiles
Physician's perspectives/KOL opinions
Biomarker testing and Patient journey
Qualitative Analysis (SWOT and Analyst Views)
RET Fusion Market Size by therapy and indication
Existing and Future Market Opportunity
Unmet Needs

FAQs:

What was the RET Fusion total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for RET Fusion market growth?
Which KRAS Inhibitor is going to be the largest contributor by 2034?
What is the market access and reimbursement scenario of RET Fusion?
What are the pricing variations among different geographies?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the RET Fusion Market.
Understand the existing RET Fusion market opportunities and future trends in varying geographies
Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

1. Key Insights

2. Report Introduction

3. Executive Summary of RET Fusion

4. Key Events

5. RET Fusion Market Overview At A Glance

5.1. Market Share (%) Distribution of RET Fusion By Therapy in 2023
5.2. Market Share (%) Distribution of RET Fusion By Therapy in 2034

6. Background And Overview

7. Target Population

8. RET Fusion Marketed Drugs

8.1. Key Competitors
8.2. Company 1: Product 1
- 8.2.1. Product Description
- 8.2.2. Regulatory Milestones
- 8.2.3. Other Developmental Activities
- 8.2.4. Ongoing Clinical Development
- 8.2.5. Safety and Efficacy
8.3. Company 2: Product 2
- 8.3.1. Product Description
- 8.3.2. Regulatory Milestones
- 8.3.3. Other Developmental Activities
- 8.3.4. Ongoing Clinical Development
- 8.3.5. Safety and Efficacy

9. RET Fusion Emerging Drugs

9.1. Key Competitors
9.2. Company 1: Product 1
- 9.2.1. Product Description
- 9.2.2. Other Development Activities
- 9.2.3. Clinical Development
  - 9.2.3.1. Clinical Trials Information
- 9.2.4. Safety and Efficacy
9.3. Company 2: Product 2
- 9.3.1. Product Description
- 9.3.2. Other Development Activities
- 9.3.3. Clinical Development
  - 9.3.3.1. Clinical Trials Information
- 9.3.4. Safety and Efficacy

10. RET Fusion: The 7MM Analysis

10.1. Key Findings
10.2. Market Outlook
10.3. Key Market Forecast Assumptions
10.4. Total Market Size of RET Fusion in the 7MM
- 10.4.1. Market Size of RET Fusion By Therapies In the 7MM
- 10.4.2. Market Size of RET Fusion By Indication In the 7MM
10.6. United States Market
- 10.6.1. Total Market Size of RET Fusion in the United States
- 10.6.2. Market Size of RET Fusion By Therapies in the United States
10.7. EU4 and the UK Market
- 10.7.1. Total Market Size of RET Fusion in EU4 and the UK
- 10.7.2. Market Size of RET Fusion By Therapies in EU4 and the UK
10.8. Japan Market
- 10.8.1. Total Market Size of RET Fusion in Japan
- 10.8.2. Market Size of RET Fusion By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

14.1. United States
- 14.1.1. Centre for Medicare & Medicaid Services (CMS)
14.2. EU4 and the UK
- 14.2.1. Germany
- 14.2.2. France
- 14.2.3. Italy
- 14.2.4. Spain
- 14.2.5. United Kingdom
14.3. Japan
- 14.3.1. MHLW